JPS6353510B2 - - Google Patents
Info
- Publication number
- JPS6353510B2 JPS6353510B2 JP56016770A JP1677081A JPS6353510B2 JP S6353510 B2 JPS6353510 B2 JP S6353510B2 JP 56016770 A JP56016770 A JP 56016770A JP 1677081 A JP1677081 A JP 1677081A JP S6353510 B2 JPS6353510 B2 JP S6353510B2
- Authority
- JP
- Japan
- Prior art keywords
- cea
- sample
- minutes
- quantification
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000523 sample Substances 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000002452 interceptive effect Effects 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 9
- 239000012470 diluted sample Substances 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 70
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 70
- 238000012360 testing method Methods 0.000 description 28
- 238000011002 quantification Methods 0.000 description 23
- 238000010438 heat treatment Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000004445 quantitative analysis Methods 0.000 description 8
- 238000002203 pretreatment Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- -1 aliphatic alcohols Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/80—Fluorescent dyes, e.g. rhodamine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Description
çèæåïŒä»¥äžCEAãšããïŒã®å®éã«ã€ããŠ
ã¯å€ãã®å ±åãããããŸãã粟床ããã³æ床ãã
å®éããããã«ã¯ã被æ€ãµã³ãã«äžã«ååšããã
ãçš®ã®éç¹ç°ç劚害ç©è³ªããªãããã®æ¹æ³ã§é€å»
ãŸãã¯äžåããªããã°ãªããªãããšãããç¥ãã
ãŠããã çç©åŠç液äœããšãã°è¡æž ãŸãã¯è¡æŒ¿äžã«ååš
ãã匷åãªåŠšå®³ç©è³ªãCEAè©Šéšåã«é€å»ãŸãã¯
äžåããæäœã«ã€ããŠã¯ããããŸã§å€ãã®æäœã
ç¥ãããŠããããäžããããåææ³ã«ããããã®
çš®ã®åŠšå®³ç©è³ªã®é€å»æäœããæéãè²»çšãŸãè©Šéš
æäœã®é£æ床ã®ç¹ã§åçŽåããããšãæå©ãªããš
ã¯ãããŸã§ããªãã ããšãã°Freedmanãã®ç±³åœç¹èš±ç¬¬3663684å·
ã®å®éæ³ã§ã¯ãè¡æž ãµã³ãã«ããŸãCEAãå¯æº¶
ã®ç³ã¿ã³ãã¯æº¶åªã§åŠçããåŸããã溶液ãæŸæ
åããããã®çš®ã®æº¶åªã®äŸãšããŠã¯éã¯ãã«é žã
äžå¡©åé ¢é žããªã³ã¿ã³ã°ã¹ãã³é žçãæããããš
ãã§ãããè¡æ¶²ãµã³ãã«ãç³ã¿ã³ãã¯æº¶åªã§åŠç
ããç®çã¯æ²æ®¿æ§ã®æ£åžžã¿ã³ãã¯ããã³åŠšå®³æå
ç©è³ªãé€å»ããããšã«ãããæ²æ®¿ãã劚害ã¿ã³ã
ã¯ç©è³ªã¯ã€ãã§é å¿åé¢ã«ãããµã³ãã«ããé€å»
ããã ããã«æè¿HiraiïŒCancer Research37ã2267
â2274ïŒ1977ïŒããã³KimãïŒClinical
Chemistry25ã773â776ïŒ1979ïŒã¯ç³ã¿ã³ãã¯æº¶
åªããšãã°éã¯ãã«é žã«ããæœåºã®ä»£ããã«æºå
ç±åŠçãçšãããµã³ãã«ã®ååŠçæ³ãå ±åããŠã
ããåŸè ã®æç®ã«ã¯ããµã³ãã«ãé ¢é žç·©è¡æ¶²ã§PH
4.8ã5.0ã«ç·©è¡åãã70âã80âã«10ã20åéå
ç±ããŠåŠšå®³ç©è³ªãé€å»ãããµã³ãã«ã®èª¿è£œæ¹æ³ã
èšèŒãããŠãããé žæ§PHã«ãããé«ã€ãªã³åŒ·åºŠç·©
è¡æ¶²äžã§ã®ãã®ç±åŠçã§ã¯ãå ç±ã«ãã劚害ã¿ã³
ãã¯ãå€æ§ããååºããããããã€ãŠãµã³ãã«ã
é å¿åé¢ããŠååºç©è³ªãé€å»ããããšãå¿ é ã«ãª
ãããã®æäœã«ã¯ããµã³ãã«äžã«ååšããCEA
ãååºç©è³ªäžã«æéããããããã€ãŠè©Šéšãµã³ã
ã«ããé€å»ãããŠããŸãã以åŸã®å®éã®ç²ŸåºŠãæ
ãããæ¬ ç¹ãããã æ¬çºæã¯CEAã®å®éåæçšããè¡æž ãŸãã¯è¡
挿ãµã³ãã«ã®ååŠçœ®æ¹æ³ãé瀺ãããã®ã§ããã
æ¬çºæã¯å ¬ç¥ã®æºåæ¹æ³ãããè¿ éã容æãã€å®
䟡ã§ãã€ãŠããµã³ãã«ã®é å¿åé¢ãå¿ èŠãšããª
ãã æ¬çºæã¯åŸæ¥çšããããŠããæ¹æ³ã«æ¯ããè¿
éã簡䟿ãã€å®äŸ¡ãªçèæåïŒCEAïŒæž¬å®çšã
ãè¡æž ãŸãã¯è¡æŒ¿ãµã³ãã«ã®ååŠçœ®æ¹æ³ãæäŸã
ããæ¬çºæã¯ãµã³ãã«ãæ°Žã§åžéãããã®ãµã³ã
ã«ã®ã€ãªã³åŒ·åºŠããã³PHã«ãããŠã¿ã³ãã¯ãååº
ããªã枩床ãããªãã¡çŽ85âããçŽ105âã奜ãŸ
ããã¯95âã«æ¯èŒççæéå ç±ããæ¹æ³ã§ããã æ¬çºæã®ååŠçœ®æ¹æ³ã®å ç±å·¥çšã§ã¯ãè©Šéšãã
æ£è è¡æž ãŸãã¯è¡æŒ¿ãµã³ãã«ãçŽïŒåããçŽ30å
å ç±ãããæ¬çºæãå®æœããã«ããã€ãŠããµã³ã
ã«ãäžèšæž©åºŠã«ä¿æããæéã«ã¯ãšãã«éå®ã¯ãª
ããäžèšç¹å®æž©åºŠã«ãµã³ãã«ãå ç±ãããããšã
å¿ èŠãªã ãã§ãã€ãŠãä¿ææéã¯çæéããšãã°
ïŒåãã10åã§ãããæ¬æ现æžã«ç€ºããå ç±æé
ã¯äŸç€ºã®ããã«ç€ºããã®ã¿ã§ãã€ãŠããµã³ãã«ã
ææã®æž©åºŠã«å ç±ãããå šãµã³ãã«ãææã®æž©åºŠ
ã«éããããšãä¿èšŒã§ããçæéããã®æž©åºŠã«ä¿
æãããã°ãããåè¿°ã®ããã«ãæ¬çºæã®æ¹æ³ã«
ããã°ãäœã€ãªã³åŒ·åºŠãäžæ§ãŸãã¯ãããã«ã¢ã«
ã«ãªæ§ã®PHã«ãããŠã¿ã³ãã¯ãååºããªã枩床ã«
å ç±ããã®ã§ãªããã°ãªããªãã è©Šéšãµã³ãã«ã®æ°Žã«ããåžéã¯ããµã³ãã«ã®ã€
ãªã³åŒ·åºŠãäœå€ãããªãã¡ããã ãæ£åžžã®ççç
ã€ãªã³åŒ·åºŠã®1/8ã®ã€ãªã³åŒ·åºŠã«ä¿ã€ããã«å¿ èŠ
ã§ããããã®åžéå·¥çšã«ã¯æ°Žéã䜿çšã§ãããã
èžçæ°ŽãŸãã¯è±ã€ãªã³æ°Žã®äœ¿çšãæãŸãããäžè¬
ã«çŽïŒïŒïŒããïŒïŒ50ã«åžéãããïŒïŒ16çšåºŠã
ãšãã«å¥œãŸããããã®ããã«åžéããããµã³ãã«
ã®ã€ãªã³åŒ·åºŠã¯äœããPHã¯äžæ§ãŸãã¯ãããã«ã¢
ã«ã«ãªæ§ãããªãã¡PHçŽïŒããçŽïŒã§ãããäžè¿°
ã®åžéç¯å²ã«ãããŠã¯ããµã³ãã«ã®åžéã«ç·©è¡å€
ãå«ãã æ°Žã䜿çšããå¿ èŠã¯ãªãããšãããã€ãŠ
ãããããããªããã以äžã®å®éã®æ床ãæ倧ã«
ããããã«ã¯ããµã³ãã«ã®åžéã«çšããæ°Žã«ã¯ç·©
è¡å€ãæ·»å ããPHããããã«ã¢ã«ã«ãªæ§ã«ç¶æã
ãããšã奜ãŸããããµã³ãã«ã®åžéã«ç·©è¡å€ãçš
ããå Žåã«ã¯ãæ £çšã¢ã«ã«ãªç·©è¡æ¶²ããšãã°ããª
ã¹ïŒããããã·ã¡ãã«ïŒã¢ããã¡ã¿ã³ç·©è¡æ¶²ãé©
åœã§ãããç·©è¡å€ã¯ãµã³ãã«ã®PHããããã«ã¢ã«
ã«ãªæ§ãããªãã¡PHçŽ7.5ããçŽ9.0ã«ä¿æããã
ãšãä¿èšŒã§ããååé䜿çšããã åŸæ¥æè¡ã®ç±åŠçæ³ã§å¿ èŠãªãµã³ãã«ã®é å¿å
é¢ãåé¿ãåŸãã®ã«å ããŠãæ¬çºæã®ååŠçã¯åŸ
æ¥æ³ã§å®çšçãšèããããŠããéãããå°ãªããµ
ã³ãã«éãããªãã¡100ÎŒã§ãã以äžã®å®éã
容æã«å®æœã§ãããããšãã°çŸåšäžè¬ã«è¡ãããŠ
ããCEAã®æŸå°å ç«å®éæ³ã§ã¯0.5mlã®ãµã³ãã«
ã䜿çšããããå ¬ç¥ã®å®éæ³ã«æ¯ã¹ãŠCEAå®é
çšã®ãµã³ãã«éãæžå°ãããããšãã§ããããã
å®éæ³ã®æ床ã«ã¯å šã圱é¿ããªããããã«ãæ¬çº
æã®ååŠçœ®æ³ã®äœ¿çšã«ãããå®éã«èŠããæéã
ãã³è²»çšãèããç¯æžãããCEAã®å®éãæ¯èŒ
ç倧èŠæš¡ã«ãããšãã°ãã¹ã¹ã¯ãªãŒãã³ã°ãè¡ã
ããšãå¯èœã«ãªããæ¬çºæã®ååŠçœ®æ³ãæ¡çšãã
å ŽåãCEAã®å šå®ééçšã¯çŽïŒæéã§å®äºããã
äžå€éæãå¿ èŠãšããçŸè¡ã®CEAå®éæ³ã«å¯Ÿãã
èããæ¹è¯ãããç¹ã§ããããããæ¬çºæã®ååŠ
眮ãè¡ã€ãã®ã¡ã®CEAã®å®éã§ã¯ãçŸè¡ã®æ¹æ³
ã«æ¯ãå®éã®æ床ã®ç¹ã§ããããŠæå©ã§ãããã
ã®ç¹ã«ã€ããŠã¯åŸè¿°ããã æ¬çºæã®ååŠçœ®æ³ã¯ãè¡æŒ¿ãŸãã¯è¡æž ãµã³ãã«
ãçŽïŒïŒïŒããçŽïŒïŒ50ã奜ãŸããã¯çŽïŒïŒ16ã«
åžéãããã®åžéãµã³ãã«ããµã³ãã«äžã«ååšã
ãã¿ã³ãã¯ã®ååºãèµ·ãããªã枩床ããªãã¡çŽ85
âããçŽ105âã奜ãŸããã¯çŽ95âã«å ç±ããæ¹
æ³ã§ãããåŸæ¥ã劚害ã¿ã³ãã¯ã¯ãµã³ãã«äžãã
ç©ççã«é€å»ãããªããã°ãªããªããšèããããŠ
ããç¹ãåŠå®ããã®ãæ¬çºæã®åçã§ããããã®
ç¹ã§æ¬çºæã¯æ°èŠã§ããã æ¬çºæã«ãã€ãŠååŠçœ®ããããµã³ãã«ã¯åžžæž©ã«
ãã©ããã€ãã§é©åœãªCEAå®éæ³ã«ä»ãããšã
ã§ãããCEAã®å ç«å®éæ³ã«ã€ããŠãã©ã®ãã
ãªæ¹æ³ãéžæãããã«ã¯ãšãã«å¶éã¯ãªããäžè¬
ã«æŸå°å ç«æ³ãŸãã¯é µçŽ å ç«æ³ã奜ãŸããããšã
ã«æŸå°å ç«ã奜ãŸããã äžè¬ã«ãCEAã®å®éã¯æ¬¡ã®ããã«è¡ãããã (a) æ£è ã®è¡æž ãŸãã¯è¡æŒ¿ãµã³ãã«ãäžè¿°ã®ãã
ã«ååŠçããŠåŒ·åãªåŠšå®³ç©è³ªãäžåããã (b) è©Šéšãµã³ãã«ã«éå°ã®CEAã«å¯Ÿããæäœã
å ãããããããå®ããããæéã€ã³ããŠããŒ
ãããã (c) æšèCEAããµã³ãã«ã«å ãããããããå®
ããããæéã€ã³ããŠããŒãããã (d) (b)ãš(c)ã®æ··åç©ã«äžæº¶åå€ãå ããæäœçµå
CEAãå«ãåºçžãšéçµåCEAãå«ã液çžãšã
çæãããã (e) åºçžãšæ¶²çžãåé¢ããã (f) åºçžãŸãã¯æ¶²çžããããã®æšèéã枬å®ã
ãã (g) æšæºæ²ç·ãšæ¯èŒããŠãµã³ãã«äžã«ååšãã
CEAéã決å®ããã äžèšå®éã«ãããŠã劚害ç©è³ªããäžåãããã®
èªãçšãããããã®èªã¯æ¬çºæã«ãããåŠçœ®ãšå
æã«ãåŸæ¥æ³ã«ããã劚害ç©è³ªã®ãµã³ãã«ããã®
ç©ççé€å»ããæå³ãããã®ã§ããããããã®å Ž
åããã®å¹æã¯åäžã§ãããããªãã¡ããã®èªã¯
劚害ç©è³ªã®å ç«åŠçäœçšãæ¶å€±ãããã®æå³ã§ã
ãã åè¿°ã®ããã«ãäžèšå®éã«ãããŠCEAãã©ã
ã«ããã®ã«çšããæšèã¯ãå®éåæã«ããé©åã
ãä»»æã®å ç«åŠçã«é©åæ§ããæšèç©è³ªãããšã
ã°æŸå°æ§åäœå çŽ ãé µçŽ ãè¢å ãããã¯ååŠçºå
ç©è³ªçã䜿çšåºãããé µçŽ ããã³æŸå°æ§åäœå çŽ
æšèã奜ãŸãããæŸå°æ§åäœå çŽ ã¯ãšãã«å¥œãŸã
ããæŸå°å ç«å®éã«æ £çšãããæŸå°æ§åäœå çŽ
äžããšãŠçŽ ã®åäœå çŽ ã奜ãŸããããšãã« 125I
ã奜ãŸããã æäœçµåCEAãå«ãåºçžããã³éçµåCEAã
å«ã液çžãçæãããã®ã«çšããäžæº¶åå€ã«ã¯ã
ã®ç®çã§æ¬æè¡åéã«ãããŠæ £çšãããŠããä»»æ
ã®ç©è³ªã䜿çšã§ãããããšãã°ãããçš®ã®èèªæ
ã¢ã«ã³ãŒã«ãã€ãªã³äº€ææš¹èããã³ç¡æ©å¡©ããªã
ã³ã«CEAæäœã«å¯ŸããæäœããæäœçµåCEAã
å«æããã¿ã³ãã¯ã®æ²æ®¿ãçæãããã奜ãŸãã
äžæº¶åå€ã¯äºæ¬¡æäœããªãã¡CEAæäœã«å¯Ÿãã
æäœã®éå¯ååããªãã¡éå¯æº¶ååã§ããã äžè¿°ã®äºæ¬¡æäœã®éå¯ååã«ã¯ãå ç«åŠçæå
ã®éå¯æº¶åã®ããã«æ¬æè¡åéã§èªããããŠãã
å€ãã®æ¹æ³ã®ãã¡ä»»æã®æ¹æ³ã䜿çšã§ãããããš
ãã°åçš®ãµã€ãºã®ç²åãããŒãºãã¹ãã€ãã¯ãŸã
ã¯æ¯æã¡ãžãŠã ã®ã¹ããªããã䜿çšã§ãããäžæº¶
åç©è³ªãšããŠéåæ§ã®ç©è³ªãããšãã°ã¹ãã¬ã³ã
ãªããŒãŸãã¯ã³ããªããŒãçšããå Žåã«ã¯ããã®
æ§è³ªã«å¿ããŠäžè¿°ã®åã®ïŒçš®ä»¥äžã®ãã®ã䜿çšã§
ãããäºæ¬¡æäœã®äžæº¶åã«ãšãã«å¥œãŸããç©è³ª
ã¯ãéåèããªïŒãããªãã³ãã«ãªã©ã€ãïŒã§ã
ããããšãã°åŸ®ç²æ«å€åãŸãã¯ãã€ã«ã ãšããŠçš
ãããããæäœã¯äžæº¶åå€äžã«ç©ççã«åžçãã
ãããŸãã¯æ¬æè¡åéã§æ £çšãããæ¹æ³ã§ååŠç
ã«çµåãããããšãã§ããã CEAå®éæã®é åæ¯çãã€ã³ããŠããŒã·ãšã³
æéããã³æž©åºŠã¯ãCEAã«é¢ããå€ãã®å ±åã
ãæ¬çºææè¡åéã®çç·Žè ã«ã¯èªæã®ãšããã§ã
ããæ¬çºæã®æ°èŠååŠçœ®æ³ãçšããŠæŸå°å ç«æ³ã§
CEAãå®éããå ŽåãçŸè¡ã®CEAå®éæ³ã«æ¯ã
ãŠææã«å°å®¹éã®ãµã³ãã«ããã³è©Šè¬ã䜿çšã§
ãããããæ床ã¯å šãæãããªãããšãæããã«
ãããŠããããã®ããå°ããè©Šéšç®¡ãèªã¿åãè£
眮ã䜿çšããã®ã䟿å©ã§ããããŸããæ¬çºæã®æ¹
æ³ã§ååŠçœ®ãããµã³ãã«ã®å ŽåãCEAã®å®éæ
äœã«äœ¿çšããCEAã«å¯Ÿããæäœã®éã¯çŽ1/5ã«æž
å°ãããããšãã§ãããçŸè¡ã®CEAæŸå°å ç«å®
éæ³ã«æ¯èŒããŠCEAã«å¯Ÿããæè¡æž ã®æšæºåã®
é »åºŠãæžå°ãããããšãã§ããããã§ããããã
ãããæèŠæéãšè²»çšãå€§å¹ ã«æžå°ããããæ¬çº
æã«ãããµã³ãã«ã®ååŠçœ®ãè¡ã€ãã®ã¡ã®CEA
ã®å®éã¯ãçŸè¡ã®CEAæŸå°å ç«å®éæ³ãCEAçŽ
20nïœïŒmlãŸã§ããæ£ç¢ºã«å®éã§ããªããšããç¹
ã§ãçŸè¡æ³ã«æ¯ã¹ãŠåªããŠãããååŠçæ³ãã¢ã
ã¿ãŒããå Žåã«ã¯ããã€ãšé«æ¿åºŠã®CEAãå®é
ããªããã°ãªããªãå Žåãããããã®ãããªé«æ¿
床ã®å®éã«ã¯ãä»ã®å®éæ³ããªãã¡çŽæ¥å®éæ³ã
æ¡çšããå¿ èŠããã€ãããã®å®éæ³ã§ã¯CEAæ¿
床ã¯æäœçŽ40nïœïŒmlããæ£ç¢ºã«å®éã§ãããã®
å€ãšçŸè¡ã®CEAæŸå°å ç«æ³ã§ã®å®ééçãšã®é
ã«ã¯çŽ20nïœïŒmlã®ã®ã€ãããæ®ã€ãŠããŸããæ¬
çºæã®æ¹æ³ã«ãã€ãŠãµã³ãã«ãååŠçœ®ããã®ã¡ã®
CEAã®å®éã§ã¯ãCEAæ¿åºŠçŽ100nïœïŒmlãŸã§æ£
確ã«å®éããããšãã§ããããã«ãã€ãŠäžè¿°ã®ã®
ã€ããã¯ãããããåæã«å®éæéãšæ£è ãèŠã
ãè²»çšãäœæžãããããšãã§ãããããªãã¡ãæ¿
床ã20nïœïŒmlãè¶ããå Žåã§ããCEAã®å®éã
äºåºŠè¡ãå¿ èŠã¯ãªãã æ¬çºæã«ããã°è©Šéšãµã³ãã«ã¯çŽ0.1mlããã°
ååã§ããµã³ãã«ããã³æšæºã®äž¡è ã«å ãã
CEAæè¡æž ãçŽ5ÎŒã§ååã§ãããæè¡æž ã®å
å¿ããã³ããã®åŸã®æšèCEAãšã®åå¿ã®å Žåã®
奜ãŸããã€ã³ããŠããŒã·ãšã³æéã¯çŽ80åããçŽ
ïŒæéã§ã90åããšãã«å¥œãŸããããããã®ã€ã³
ããŠããŒã·ãšã³ã¯çŽ45âã§å®æœããããé µçŽ æšè
ã䜿çšããå Žåã«ã¯ãäžè¿°ã®æž©åºŠã§é µçŽ ãäžå®å®
ã§ããã°ãé µçŽ ã®äžæŽ»æ§åãé²æ¢ããããã«ãã€
ã³ããŠããŒã·ãšã³æéããã³æž©åºŠãé©åœã«èª¿æŽã
ãå¿ èŠããããéå¯ååäºæ¬¡æäœãäžæº¶åå€ãšã
ãŠäœ¿çšããå Žåã¯ããµã³ãã«ã¯åžžæž©ã§çŽ15åãã
çŽ30åã奜ãŸããã¯çŽ20åã€ã³ããŠããŒãããã
ãµã³ãã«äžã®CEAã®å®éã¯åžžæ³ã«ããæšæºæ²ç·
ãšæ¯èŒããŠè¡ããæšèã®æ¿åºŠã®æž¬å®ãåæ§ã«æšè
ã®çš®é¡ã«å¿ããŠåžžæ³ã§å®æœãããæŸå°æ§åäœå çŽ
ãçšããå Žåã¯ã¬ã³ããŒã·ã³ãã¬ãŒã·ãšã³ã¹ãã¯
ããã¡ãŒã¿ãŒã䜿çšããã 次ã«æ¬çºæã以äžã®å®æœäŸã«ãã€ãŠããã«è©³çŽ°
ã«èª¬æããããšãã«æ瀺ã®ãªãéãã枩床ã¯ãã¹
ãŠææ°ã§è¡šç€ºããã äŸ ïŒ çŸè¡ã®CEAã®å®éã¯æ¬¡ã®ããã«è¡ãããã çµè žçãçãããæ£è ã®è¡æŒ¿ïŒäºéæ³ã§ïŒãµã³
ãã«ïŒ0.5mlïŒãå·1.2ã¢ã«éå¡©çŽ é ž2.5mlã«ããã
ãããŸãåæ··åæ©ãçšã30ç§éæœåºãã1000Ãïœ
ã§20åéé å¿åé¢ãããäžæŸæ¶²ãéããŠéæè¢ã«
移ããè±ã€ãªã³æ°Žã«å¯ŸããæäœïŒæéééã§ïŒå
æ°Žã亀æããŠéæãããæçµéæ液ãé ¢é žã¢ã³ã¢
ããŠã ç·©è¡æ¶²ã§åŠçããŠãPHãçŽ6.5ãšãããé
æåŸãéæè¢ã®å 容ãè©Šéšç®¡ã«ç§»ããåžè²©CEA
æè¡æž å25ÎŒããããŸãåæ··åæ©ã§æ··åããªã
ãå ãããè©Šéšç®¡ãïŒåéã45âã§ã€ã³ããŠããŒ
ããããåè©Šéšç®¡ã« 125IâCEA25ÎŒãæ··åããª
ããªå ãã45âã§åã³30åéã€ã³ããŠããŒãã
ããèš2.5mlã®ãžã«ã³ãã«ãã¹ããšãŒãã²ã«PH
6.25ãåè©Šéšç®¡ã«å ããå 容ç©ã1000Ãïœã§ïŒå
éé å¿åé¢ãããäžæŸæ¶²ãé€å»ããïŒmlã®é ¢é žã¢
ã³ã¢ããŠã ç·©è¡æ¶²PH6.25ãæ··åããªããå ããã
è©Šéšç®¡ã®å 容ç©ãåã³ååãšåæ§ã«é å¿åé¢ãã
äžæŸæ¶²ãé€å»ãããæ®ã€ãã²ã«äžã®çµå 125Iâ
CEAéãã¬ã³ããŒã·ã³ãã¬ãŒã·ãšã³ã¹ãã¯ãã
ã¡ãŒã¿ãŒã§ïŒåéã«ãŠã³ãããŠæž¬å®ããã æšæºé»æ¢æ²ç·ã¯æ¬¡ã®ããã«ããŠäœæããã è©Šéšç®¡ã察ã«ããŠæºåããïŒïŒ10ã«è±ã€ãªã³æ°Ž
ã§åžéããEDTAç·©è¡æ¶²ïŒPH6.5ïŒ5.0mlãå ã
ããå察ã®è©Šéšç®¡ã«æšæºéã®CEAããªãã¡ïŒã
1.25ã3.125ã6.25ããã³12.5nïœïŒmlCEA掻æ§ã«
çžåœããïŒã10ã25ã50ããã³100ÎŒãå ãã
å 容ç©ããããŸãåæ··åæ©ã§æ··åãããã€ãã§è©Š
éšç®¡ãäžè¿°ã®æ¹æ³ãšåæ§ã«ããŠCEAã®æè¡æž ã
ãã³ 125IâCEAã§åŠçãããåèªã¿åãå€ãã
æšæºæ²ç·ãäœæããæ£è ãµã³ãã«ã«ã€ããŠåŸãã
ãå€ãšæ¯èŒããã äŸ ïŒ æ¬çºæã«ãã€ãŠååŠçãããµã³ãã«ã®CEAå®
éã以äžã®ãšããå®æœããã è¡æŒ¿ãµã³ãã«ïŒ0.1mlïŒãè±ã€ãªã³æ°Ž1.5mlã§åž
éãããã«ããã¯ã¹åæ··åæ©ã§æ··åãããè©Šéšç®¡
ã95âã®æ°ŽæµŽã«10åéã€ããã®ã¡åãåºãã宀枩
ã«æŸå·ãããåè©Šéšç®¡ã«åžè²©CEAæè¡æž 5ÎŒã
ãããŸãåæ··åæ©ã§æ··åããªããå ãããè©Šéšç®¡
ã45âã§90åéã€ã³ããŠããŒããããåè©Šéšç®¡ã«
125IâCEA25ÎŒãæ··åããªããå ããè©Šéšç®¡ã
45âã§90åéåã³ã€ã³ããŠããŒããããåè©Šéšç®¡
ã«ãããªïŒãããªãã³ãã«ãªã©ã€ãïŒã®ç²åã«åž
çäžæº¶åããCEAæè¡æž ã«å¯Ÿããæäœã®æ°Žæžæ¿
液500ÎŒãå ãããè©Šéšç®¡ãåã³æ··åãã宀枩
ã§20åéã€ã³ããŠããŒããããã€ãã§ãµã³ãã«ã
1000Ãïœã§10åéé å¿åé¢ãããäžæŸæ¶²ãåŸç
ããè©Šéšç®¡ãã¬ã³ããŒã·ã³ãã¬ãŒã·ãšã³ã¹ãã¯ã
ãã¡ãŒã¿ãŒã§ã«ãŠã³ãããã æšæºé»æ¢æ²ç·ã¯æ¬¡ã®ããã«ããŠäœæããã è©Šéšç®¡ã察ã«ããåçµä¹Ÿç¥ããè¡æž ãåçãã
è±ã€ãªã³æ°Ž1.5mlã§åžéãã液0.1mlãå ãããè©Š
éšç®¡ã®å 容ç©ããããŸãåæ··ååã§æ··åãã95â
ã§10åéã€ã³ããŠããŒããããå察ã®è©Šéšç®¡ã«æš
æºéã®CEAããªãã¡ãïŒã0.625ã1.25ã3.125ã
6.25ããã³12.5nïœïŒmlCEA掻æ§ã«çžåœããïŒã
ïŒã10ã25ã50ããã³100ÎŒãå ããå 容ç©ã
ãããŸãåæ··åæ©ã§æ··åãããã€ãã§è©Šéšç®¡ãäž
è¿°ã®æ¹æ³ãšåæ§ã«ããŠCEAã®æè¡æž ã 125Iâ
CEAããã³äžæº¶åäºæ¬¡æäœã§åŠçãããåèªã¿
åãå€ããæšæºæ²ç·ãäœæããæ£è è¡æŒ¿ãµã³ãã«
ã«ã€ããŠåŸãããå€ãšæ¯èŒããã 第ïŒè¡šã¯äŸïŒã®åŸæ¥æ³ã®éææ³ã§åŸããããµã³
ãã«ã«ã€ããŠã®çµæãããã³äŸïŒã®æ¬çºæã®æ¹æ³
ã§åŸããããµã³ãã«ã«ã€ããŠã®çµæã§ããã 第ïŒè¡šã®çµæã¯ãCEAæ¿åºŠ20nïœïŒmlãŸã§ã¯äŸ
ïŒããã³äŸïŒã®æ¹æ³ãããçžé¢ããçžé¢ä¿æ°ã¯
0.963ãåŸé ã¯1.03ã§ããããšã瀺ããŠããã
ã¯å€ãã®å ±åãããããŸãã粟床ããã³æ床ãã
å®éããããã«ã¯ã被æ€ãµã³ãã«äžã«ååšããã
ãçš®ã®éç¹ç°ç劚害ç©è³ªããªãããã®æ¹æ³ã§é€å»
ãŸãã¯äžåããªããã°ãªããªãããšãããç¥ãã
ãŠããã çç©åŠç液äœããšãã°è¡æž ãŸãã¯è¡æŒ¿äžã«ååš
ãã匷åãªåŠšå®³ç©è³ªãCEAè©Šéšåã«é€å»ãŸãã¯
äžåããæäœã«ã€ããŠã¯ããããŸã§å€ãã®æäœã
ç¥ãããŠããããäžããããåææ³ã«ããããã®
çš®ã®åŠšå®³ç©è³ªã®é€å»æäœããæéãè²»çšãŸãè©Šéš
æäœã®é£æ床ã®ç¹ã§åçŽåããããšãæå©ãªããš
ã¯ãããŸã§ããªãã ããšãã°Freedmanãã®ç±³åœç¹èš±ç¬¬3663684å·
ã®å®éæ³ã§ã¯ãè¡æž ãµã³ãã«ããŸãCEAãå¯æº¶
ã®ç³ã¿ã³ãã¯æº¶åªã§åŠçããåŸããã溶液ãæŸæ
åããããã®çš®ã®æº¶åªã®äŸãšããŠã¯éã¯ãã«é žã
äžå¡©åé ¢é žããªã³ã¿ã³ã°ã¹ãã³é žçãæããããš
ãã§ãããè¡æ¶²ãµã³ãã«ãç³ã¿ã³ãã¯æº¶åªã§åŠç
ããç®çã¯æ²æ®¿æ§ã®æ£åžžã¿ã³ãã¯ããã³åŠšå®³æå
ç©è³ªãé€å»ããããšã«ãããæ²æ®¿ãã劚害ã¿ã³ã
ã¯ç©è³ªã¯ã€ãã§é å¿åé¢ã«ãããµã³ãã«ããé€å»
ããã ããã«æè¿HiraiïŒCancer Research37ã2267
â2274ïŒ1977ïŒããã³KimãïŒClinical
Chemistry25ã773â776ïŒ1979ïŒã¯ç³ã¿ã³ãã¯æº¶
åªããšãã°éã¯ãã«é žã«ããæœåºã®ä»£ããã«æºå
ç±åŠçãçšãããµã³ãã«ã®ååŠçæ³ãå ±åããŠã
ããåŸè ã®æç®ã«ã¯ããµã³ãã«ãé ¢é žç·©è¡æ¶²ã§PH
4.8ã5.0ã«ç·©è¡åãã70âã80âã«10ã20åéå
ç±ããŠåŠšå®³ç©è³ªãé€å»ãããµã³ãã«ã®èª¿è£œæ¹æ³ã
èšèŒãããŠãããé žæ§PHã«ãããé«ã€ãªã³åŒ·åºŠç·©
è¡æ¶²äžã§ã®ãã®ç±åŠçã§ã¯ãå ç±ã«ãã劚害ã¿ã³
ãã¯ãå€æ§ããååºããããããã€ãŠãµã³ãã«ã
é å¿åé¢ããŠååºç©è³ªãé€å»ããããšãå¿ é ã«ãª
ãããã®æäœã«ã¯ããµã³ãã«äžã«ååšããCEA
ãååºç©è³ªäžã«æéããããããã€ãŠè©Šéšãµã³ã
ã«ããé€å»ãããŠããŸãã以åŸã®å®éã®ç²ŸåºŠãæ
ãããæ¬ ç¹ãããã æ¬çºæã¯CEAã®å®éåæçšããè¡æž ãŸãã¯è¡
挿ãµã³ãã«ã®ååŠçœ®æ¹æ³ãé瀺ãããã®ã§ããã
æ¬çºæã¯å ¬ç¥ã®æºåæ¹æ³ãããè¿ éã容æãã€å®
䟡ã§ãã€ãŠããµã³ãã«ã®é å¿åé¢ãå¿ èŠãšããª
ãã æ¬çºæã¯åŸæ¥çšããããŠããæ¹æ³ã«æ¯ããè¿
éã簡䟿ãã€å®äŸ¡ãªçèæåïŒCEAïŒæž¬å®çšã
ãè¡æž ãŸãã¯è¡æŒ¿ãµã³ãã«ã®ååŠçœ®æ¹æ³ãæäŸã
ããæ¬çºæã¯ãµã³ãã«ãæ°Žã§åžéãããã®ãµã³ã
ã«ã®ã€ãªã³åŒ·åºŠããã³PHã«ãããŠã¿ã³ãã¯ãååº
ããªã枩床ãããªãã¡çŽ85âããçŽ105âã奜ãŸ
ããã¯95âã«æ¯èŒççæéå ç±ããæ¹æ³ã§ããã æ¬çºæã®ååŠçœ®æ¹æ³ã®å ç±å·¥çšã§ã¯ãè©Šéšãã
æ£è è¡æž ãŸãã¯è¡æŒ¿ãµã³ãã«ãçŽïŒåããçŽ30å
å ç±ãããæ¬çºæãå®æœããã«ããã€ãŠããµã³ã
ã«ãäžèšæž©åºŠã«ä¿æããæéã«ã¯ãšãã«éå®ã¯ãª
ããäžèšç¹å®æž©åºŠã«ãµã³ãã«ãå ç±ãããããšã
å¿ èŠãªã ãã§ãã€ãŠãä¿ææéã¯çæéããšãã°
ïŒåãã10åã§ãããæ¬æ现æžã«ç€ºããå ç±æé
ã¯äŸç€ºã®ããã«ç€ºããã®ã¿ã§ãã€ãŠããµã³ãã«ã
ææã®æž©åºŠã«å ç±ãããå šãµã³ãã«ãææã®æž©åºŠ
ã«éããããšãä¿èšŒã§ããçæéããã®æž©åºŠã«ä¿
æãããã°ãããåè¿°ã®ããã«ãæ¬çºæã®æ¹æ³ã«
ããã°ãäœã€ãªã³åŒ·åºŠãäžæ§ãŸãã¯ãããã«ã¢ã«
ã«ãªæ§ã®PHã«ãããŠã¿ã³ãã¯ãååºããªã枩床ã«
å ç±ããã®ã§ãªããã°ãªããªãã è©Šéšãµã³ãã«ã®æ°Žã«ããåžéã¯ããµã³ãã«ã®ã€
ãªã³åŒ·åºŠãäœå€ãããªãã¡ããã ãæ£åžžã®ççç
ã€ãªã³åŒ·åºŠã®1/8ã®ã€ãªã³åŒ·åºŠã«ä¿ã€ããã«å¿ èŠ
ã§ããããã®åžéå·¥çšã«ã¯æ°Žéã䜿çšã§ãããã
èžçæ°ŽãŸãã¯è±ã€ãªã³æ°Žã®äœ¿çšãæãŸãããäžè¬
ã«çŽïŒïŒïŒããïŒïŒ50ã«åžéãããïŒïŒ16çšåºŠã
ãšãã«å¥œãŸããããã®ããã«åžéããããµã³ãã«
ã®ã€ãªã³åŒ·åºŠã¯äœããPHã¯äžæ§ãŸãã¯ãããã«ã¢
ã«ã«ãªæ§ãããªãã¡PHçŽïŒããçŽïŒã§ãããäžè¿°
ã®åžéç¯å²ã«ãããŠã¯ããµã³ãã«ã®åžéã«ç·©è¡å€
ãå«ãã æ°Žã䜿çšããå¿ èŠã¯ãªãããšãããã€ãŠ
ãããããããªããã以äžã®å®éã®æ床ãæ倧ã«
ããããã«ã¯ããµã³ãã«ã®åžéã«çšããæ°Žã«ã¯ç·©
è¡å€ãæ·»å ããPHããããã«ã¢ã«ã«ãªæ§ã«ç¶æã
ãããšã奜ãŸããããµã³ãã«ã®åžéã«ç·©è¡å€ãçš
ããå Žåã«ã¯ãæ £çšã¢ã«ã«ãªç·©è¡æ¶²ããšãã°ããª
ã¹ïŒããããã·ã¡ãã«ïŒã¢ããã¡ã¿ã³ç·©è¡æ¶²ãé©
åœã§ãããç·©è¡å€ã¯ãµã³ãã«ã®PHããããã«ã¢ã«
ã«ãªæ§ãããªãã¡PHçŽ7.5ããçŽ9.0ã«ä¿æããã
ãšãä¿èšŒã§ããååé䜿çšããã åŸæ¥æè¡ã®ç±åŠçæ³ã§å¿ èŠãªãµã³ãã«ã®é å¿å
é¢ãåé¿ãåŸãã®ã«å ããŠãæ¬çºæã®ååŠçã¯åŸ
æ¥æ³ã§å®çšçãšèããããŠããéãããå°ãªããµ
ã³ãã«éãããªãã¡100ÎŒã§ãã以äžã®å®éã
容æã«å®æœã§ãããããšãã°çŸåšäžè¬ã«è¡ãããŠ
ããCEAã®æŸå°å ç«å®éæ³ã§ã¯0.5mlã®ãµã³ãã«
ã䜿çšããããå ¬ç¥ã®å®éæ³ã«æ¯ã¹ãŠCEAå®é
çšã®ãµã³ãã«éãæžå°ãããããšãã§ããããã
å®éæ³ã®æ床ã«ã¯å šã圱é¿ããªããããã«ãæ¬çº
æã®ååŠçœ®æ³ã®äœ¿çšã«ãããå®éã«èŠããæéã
ãã³è²»çšãèããç¯æžãããCEAã®å®éãæ¯èŒ
ç倧èŠæš¡ã«ãããšãã°ãã¹ã¹ã¯ãªãŒãã³ã°ãè¡ã
ããšãå¯èœã«ãªããæ¬çºæã®ååŠçœ®æ³ãæ¡çšãã
å ŽåãCEAã®å šå®ééçšã¯çŽïŒæéã§å®äºããã
äžå€éæãå¿ èŠãšããçŸè¡ã®CEAå®éæ³ã«å¯Ÿãã
èããæ¹è¯ãããç¹ã§ããããããæ¬çºæã®ååŠ
眮ãè¡ã€ãã®ã¡ã®CEAã®å®éã§ã¯ãçŸè¡ã®æ¹æ³
ã«æ¯ãå®éã®æ床ã®ç¹ã§ããããŠæå©ã§ãããã
ã®ç¹ã«ã€ããŠã¯åŸè¿°ããã æ¬çºæã®ååŠçœ®æ³ã¯ãè¡æŒ¿ãŸãã¯è¡æž ãµã³ãã«
ãçŽïŒïŒïŒããçŽïŒïŒ50ã奜ãŸããã¯çŽïŒïŒ16ã«
åžéãããã®åžéãµã³ãã«ããµã³ãã«äžã«ååšã
ãã¿ã³ãã¯ã®ååºãèµ·ãããªã枩床ããªãã¡çŽ85
âããçŽ105âã奜ãŸããã¯çŽ95âã«å ç±ããæ¹
æ³ã§ãããåŸæ¥ã劚害ã¿ã³ãã¯ã¯ãµã³ãã«äžãã
ç©ççã«é€å»ãããªããã°ãªããªããšèããããŠ
ããç¹ãåŠå®ããã®ãæ¬çºæã®åçã§ããããã®
ç¹ã§æ¬çºæã¯æ°èŠã§ããã æ¬çºæã«ãã€ãŠååŠçœ®ããããµã³ãã«ã¯åžžæž©ã«
ãã©ããã€ãã§é©åœãªCEAå®éæ³ã«ä»ãããšã
ã§ãããCEAã®å ç«å®éæ³ã«ã€ããŠãã©ã®ãã
ãªæ¹æ³ãéžæãããã«ã¯ãšãã«å¶éã¯ãªããäžè¬
ã«æŸå°å ç«æ³ãŸãã¯é µçŽ å ç«æ³ã奜ãŸããããšã
ã«æŸå°å ç«ã奜ãŸããã äžè¬ã«ãCEAã®å®éã¯æ¬¡ã®ããã«è¡ãããã (a) æ£è ã®è¡æž ãŸãã¯è¡æŒ¿ãµã³ãã«ãäžè¿°ã®ãã
ã«ååŠçããŠåŒ·åãªåŠšå®³ç©è³ªãäžåããã (b) è©Šéšãµã³ãã«ã«éå°ã®CEAã«å¯Ÿããæäœã
å ãããããããå®ããããæéã€ã³ããŠããŒ
ãããã (c) æšèCEAããµã³ãã«ã«å ãããããããå®
ããããæéã€ã³ããŠããŒãããã (d) (b)ãš(c)ã®æ··åç©ã«äžæº¶åå€ãå ããæäœçµå
CEAãå«ãåºçžãšéçµåCEAãå«ã液çžãšã
çæãããã (e) åºçžãšæ¶²çžãåé¢ããã (f) åºçžãŸãã¯æ¶²çžããããã®æšèéã枬å®ã
ãã (g) æšæºæ²ç·ãšæ¯èŒããŠãµã³ãã«äžã«ååšãã
CEAéã決å®ããã äžèšå®éã«ãããŠã劚害ç©è³ªããäžåãããã®
èªãçšãããããã®èªã¯æ¬çºæã«ãããåŠçœ®ãšå
æã«ãåŸæ¥æ³ã«ããã劚害ç©è³ªã®ãµã³ãã«ããã®
ç©ççé€å»ããæå³ãããã®ã§ããããããã®å Ž
åããã®å¹æã¯åäžã§ãããããªãã¡ããã®èªã¯
劚害ç©è³ªã®å ç«åŠçäœçšãæ¶å€±ãããã®æå³ã§ã
ãã åè¿°ã®ããã«ãäžèšå®éã«ãããŠCEAãã©ã
ã«ããã®ã«çšããæšèã¯ãå®éåæã«ããé©åã
ãä»»æã®å ç«åŠçã«é©åæ§ããæšèç©è³ªãããšã
ã°æŸå°æ§åäœå çŽ ãé µçŽ ãè¢å ãããã¯ååŠçºå
ç©è³ªçã䜿çšåºãããé µçŽ ããã³æŸå°æ§åäœå çŽ
æšèã奜ãŸãããæŸå°æ§åäœå çŽ ã¯ãšãã«å¥œãŸã
ããæŸå°å ç«å®éã«æ £çšãããæŸå°æ§åäœå çŽ
äžããšãŠçŽ ã®åäœå çŽ ã奜ãŸããããšãã« 125I
ã奜ãŸããã æäœçµåCEAãå«ãåºçžããã³éçµåCEAã
å«ã液çžãçæãããã®ã«çšããäžæº¶åå€ã«ã¯ã
ã®ç®çã§æ¬æè¡åéã«ãããŠæ £çšãããŠããä»»æ
ã®ç©è³ªã䜿çšã§ãããããšãã°ãããçš®ã®èèªæ
ã¢ã«ã³ãŒã«ãã€ãªã³äº€ææš¹èããã³ç¡æ©å¡©ããªã
ã³ã«CEAæäœã«å¯ŸããæäœããæäœçµåCEAã
å«æããã¿ã³ãã¯ã®æ²æ®¿ãçæãããã奜ãŸãã
äžæº¶åå€ã¯äºæ¬¡æäœããªãã¡CEAæäœã«å¯Ÿãã
æäœã®éå¯ååããªãã¡éå¯æº¶ååã§ããã äžè¿°ã®äºæ¬¡æäœã®éå¯ååã«ã¯ãå ç«åŠçæå
ã®éå¯æº¶åã®ããã«æ¬æè¡åéã§èªããããŠãã
å€ãã®æ¹æ³ã®ãã¡ä»»æã®æ¹æ³ã䜿çšã§ãããããš
ãã°åçš®ãµã€ãºã®ç²åãããŒãºãã¹ãã€ãã¯ãŸã
ã¯æ¯æã¡ãžãŠã ã®ã¹ããªããã䜿çšã§ãããäžæº¶
åç©è³ªãšããŠéåæ§ã®ç©è³ªãããšãã°ã¹ãã¬ã³ã
ãªããŒãŸãã¯ã³ããªããŒãçšããå Žåã«ã¯ããã®
æ§è³ªã«å¿ããŠäžè¿°ã®åã®ïŒçš®ä»¥äžã®ãã®ã䜿çšã§
ãããäºæ¬¡æäœã®äžæº¶åã«ãšãã«å¥œãŸããç©è³ª
ã¯ãéåèããªïŒãããªãã³ãã«ãªã©ã€ãïŒã§ã
ããããšãã°åŸ®ç²æ«å€åãŸãã¯ãã€ã«ã ãšããŠçš
ãããããæäœã¯äžæº¶åå€äžã«ç©ççã«åžçãã
ãããŸãã¯æ¬æè¡åéã§æ £çšãããæ¹æ³ã§ååŠç
ã«çµåãããããšãã§ããã CEAå®éæã®é åæ¯çãã€ã³ããŠããŒã·ãšã³
æéããã³æž©åºŠã¯ãCEAã«é¢ããå€ãã®å ±åã
ãæ¬çºææè¡åéã®çç·Žè ã«ã¯èªæã®ãšããã§ã
ããæ¬çºæã®æ°èŠååŠçœ®æ³ãçšããŠæŸå°å ç«æ³ã§
CEAãå®éããå ŽåãçŸè¡ã®CEAå®éæ³ã«æ¯ã
ãŠææã«å°å®¹éã®ãµã³ãã«ããã³è©Šè¬ã䜿çšã§
ãããããæ床ã¯å šãæãããªãããšãæããã«
ãããŠããããã®ããå°ããè©Šéšç®¡ãèªã¿åãè£
眮ã䜿çšããã®ã䟿å©ã§ããããŸããæ¬çºæã®æ¹
æ³ã§ååŠçœ®ãããµã³ãã«ã®å ŽåãCEAã®å®éæ
äœã«äœ¿çšããCEAã«å¯Ÿããæäœã®éã¯çŽ1/5ã«æž
å°ãããããšãã§ãããçŸè¡ã®CEAæŸå°å ç«å®
éæ³ã«æ¯èŒããŠCEAã«å¯Ÿããæè¡æž ã®æšæºåã®
é »åºŠãæžå°ãããããšãã§ããããã§ããããã
ãããæèŠæéãšè²»çšãå€§å¹ ã«æžå°ããããæ¬çº
æã«ãããµã³ãã«ã®ååŠçœ®ãè¡ã€ãã®ã¡ã®CEA
ã®å®éã¯ãçŸè¡ã®CEAæŸå°å ç«å®éæ³ãCEAçŽ
20nïœïŒmlãŸã§ããæ£ç¢ºã«å®éã§ããªããšããç¹
ã§ãçŸè¡æ³ã«æ¯ã¹ãŠåªããŠãããååŠçæ³ãã¢ã
ã¿ãŒããå Žåã«ã¯ããã€ãšé«æ¿åºŠã®CEAãå®é
ããªããã°ãªããªãå Žåãããããã®ãããªé«æ¿
床ã®å®éã«ã¯ãä»ã®å®éæ³ããªãã¡çŽæ¥å®éæ³ã
æ¡çšããå¿ èŠããã€ãããã®å®éæ³ã§ã¯CEAæ¿
床ã¯æäœçŽ40nïœïŒmlããæ£ç¢ºã«å®éã§ãããã®
å€ãšçŸè¡ã®CEAæŸå°å ç«æ³ã§ã®å®ééçãšã®é
ã«ã¯çŽ20nïœïŒmlã®ã®ã€ãããæ®ã€ãŠããŸããæ¬
çºæã®æ¹æ³ã«ãã€ãŠãµã³ãã«ãååŠçœ®ããã®ã¡ã®
CEAã®å®éã§ã¯ãCEAæ¿åºŠçŽ100nïœïŒmlãŸã§æ£
確ã«å®éããããšãã§ããããã«ãã€ãŠäžè¿°ã®ã®
ã€ããã¯ãããããåæã«å®éæéãšæ£è ãèŠã
ãè²»çšãäœæžãããããšãã§ãããããªãã¡ãæ¿
床ã20nïœïŒmlãè¶ããå Žåã§ããCEAã®å®éã
äºåºŠè¡ãå¿ èŠã¯ãªãã æ¬çºæã«ããã°è©Šéšãµã³ãã«ã¯çŽ0.1mlããã°
ååã§ããµã³ãã«ããã³æšæºã®äž¡è ã«å ãã
CEAæè¡æž ãçŽ5ÎŒã§ååã§ãããæè¡æž ã®å
å¿ããã³ããã®åŸã®æšèCEAãšã®åå¿ã®å Žåã®
奜ãŸããã€ã³ããŠããŒã·ãšã³æéã¯çŽ80åããçŽ
ïŒæéã§ã90åããšãã«å¥œãŸããããããã®ã€ã³
ããŠããŒã·ãšã³ã¯çŽ45âã§å®æœããããé µçŽ æšè
ã䜿çšããå Žåã«ã¯ãäžè¿°ã®æž©åºŠã§é µçŽ ãäžå®å®
ã§ããã°ãé µçŽ ã®äžæŽ»æ§åãé²æ¢ããããã«ãã€
ã³ããŠããŒã·ãšã³æéããã³æž©åºŠãé©åœã«èª¿æŽã
ãå¿ èŠããããéå¯ååäºæ¬¡æäœãäžæº¶åå€ãšã
ãŠäœ¿çšããå Žåã¯ããµã³ãã«ã¯åžžæž©ã§çŽ15åãã
çŽ30åã奜ãŸããã¯çŽ20åã€ã³ããŠããŒãããã
ãµã³ãã«äžã®CEAã®å®éã¯åžžæ³ã«ããæšæºæ²ç·
ãšæ¯èŒããŠè¡ããæšèã®æ¿åºŠã®æž¬å®ãåæ§ã«æšè
ã®çš®é¡ã«å¿ããŠåžžæ³ã§å®æœãããæŸå°æ§åäœå çŽ
ãçšããå Žåã¯ã¬ã³ããŒã·ã³ãã¬ãŒã·ãšã³ã¹ãã¯
ããã¡ãŒã¿ãŒã䜿çšããã 次ã«æ¬çºæã以äžã®å®æœäŸã«ãã€ãŠããã«è©³çŽ°
ã«èª¬æããããšãã«æ瀺ã®ãªãéãã枩床ã¯ãã¹
ãŠææ°ã§è¡šç€ºããã äŸ ïŒ çŸè¡ã®CEAã®å®éã¯æ¬¡ã®ããã«è¡ãããã çµè žçãçãããæ£è ã®è¡æŒ¿ïŒäºéæ³ã§ïŒãµã³
ãã«ïŒ0.5mlïŒãå·1.2ã¢ã«éå¡©çŽ é ž2.5mlã«ããã
ãããŸãåæ··åæ©ãçšã30ç§éæœåºãã1000Ãïœ
ã§20åéé å¿åé¢ãããäžæŸæ¶²ãéããŠéæè¢ã«
移ããè±ã€ãªã³æ°Žã«å¯ŸããæäœïŒæéééã§ïŒå
æ°Žã亀æããŠéæãããæçµéæ液ãé ¢é žã¢ã³ã¢
ããŠã ç·©è¡æ¶²ã§åŠçããŠãPHãçŽ6.5ãšãããé
æåŸãéæè¢ã®å 容ãè©Šéšç®¡ã«ç§»ããåžè²©CEA
æè¡æž å25ÎŒããããŸãåæ··åæ©ã§æ··åããªã
ãå ãããè©Šéšç®¡ãïŒåéã45âã§ã€ã³ããŠããŒ
ããããåè©Šéšç®¡ã« 125IâCEA25ÎŒãæ··åããª
ããªå ãã45âã§åã³30åéã€ã³ããŠããŒãã
ããèš2.5mlã®ãžã«ã³ãã«ãã¹ããšãŒãã²ã«PH
6.25ãåè©Šéšç®¡ã«å ããå 容ç©ã1000Ãïœã§ïŒå
éé å¿åé¢ãããäžæŸæ¶²ãé€å»ããïŒmlã®é ¢é žã¢
ã³ã¢ããŠã ç·©è¡æ¶²PH6.25ãæ··åããªããå ããã
è©Šéšç®¡ã®å 容ç©ãåã³ååãšåæ§ã«é å¿åé¢ãã
äžæŸæ¶²ãé€å»ãããæ®ã€ãã²ã«äžã®çµå 125Iâ
CEAéãã¬ã³ããŒã·ã³ãã¬ãŒã·ãšã³ã¹ãã¯ãã
ã¡ãŒã¿ãŒã§ïŒåéã«ãŠã³ãããŠæž¬å®ããã æšæºé»æ¢æ²ç·ã¯æ¬¡ã®ããã«ããŠäœæããã è©Šéšç®¡ã察ã«ããŠæºåããïŒïŒ10ã«è±ã€ãªã³æ°Ž
ã§åžéããEDTAç·©è¡æ¶²ïŒPH6.5ïŒ5.0mlãå ã
ããå察ã®è©Šéšç®¡ã«æšæºéã®CEAããªãã¡ïŒã
1.25ã3.125ã6.25ããã³12.5nïœïŒmlCEA掻æ§ã«
çžåœããïŒã10ã25ã50ããã³100ÎŒãå ãã
å 容ç©ããããŸãåæ··åæ©ã§æ··åãããã€ãã§è©Š
éšç®¡ãäžè¿°ã®æ¹æ³ãšåæ§ã«ããŠCEAã®æè¡æž ã
ãã³ 125IâCEAã§åŠçãããåèªã¿åãå€ãã
æšæºæ²ç·ãäœæããæ£è ãµã³ãã«ã«ã€ããŠåŸãã
ãå€ãšæ¯èŒããã äŸ ïŒ æ¬çºæã«ãã€ãŠååŠçãããµã³ãã«ã®CEAå®
éã以äžã®ãšããå®æœããã è¡æŒ¿ãµã³ãã«ïŒ0.1mlïŒãè±ã€ãªã³æ°Ž1.5mlã§åž
éãããã«ããã¯ã¹åæ··åæ©ã§æ··åãããè©Šéšç®¡
ã95âã®æ°ŽæµŽã«10åéã€ããã®ã¡åãåºãã宀枩
ã«æŸå·ãããåè©Šéšç®¡ã«åžè²©CEAæè¡æž 5ÎŒã
ãããŸãåæ··åæ©ã§æ··åããªããå ãããè©Šéšç®¡
ã45âã§90åéã€ã³ããŠããŒããããåè©Šéšç®¡ã«
125IâCEA25ÎŒãæ··åããªããå ããè©Šéšç®¡ã
45âã§90åéåã³ã€ã³ããŠããŒããããåè©Šéšç®¡
ã«ãããªïŒãããªãã³ãã«ãªã©ã€ãïŒã®ç²åã«åž
çäžæº¶åããCEAæè¡æž ã«å¯Ÿããæäœã®æ°Žæžæ¿
液500ÎŒãå ãããè©Šéšç®¡ãåã³æ··åãã宀枩
ã§20åéã€ã³ããŠããŒããããã€ãã§ãµã³ãã«ã
1000Ãïœã§10åéé å¿åé¢ãããäžæŸæ¶²ãåŸç
ããè©Šéšç®¡ãã¬ã³ããŒã·ã³ãã¬ãŒã·ãšã³ã¹ãã¯ã
ãã¡ãŒã¿ãŒã§ã«ãŠã³ãããã æšæºé»æ¢æ²ç·ã¯æ¬¡ã®ããã«ããŠäœæããã è©Šéšç®¡ã察ã«ããåçµä¹Ÿç¥ããè¡æž ãåçãã
è±ã€ãªã³æ°Ž1.5mlã§åžéãã液0.1mlãå ãããè©Š
éšç®¡ã®å 容ç©ããããŸãåæ··ååã§æ··åãã95â
ã§10åéã€ã³ããŠããŒããããå察ã®è©Šéšç®¡ã«æš
æºéã®CEAããªãã¡ãïŒã0.625ã1.25ã3.125ã
6.25ããã³12.5nïœïŒmlCEA掻æ§ã«çžåœããïŒã
ïŒã10ã25ã50ããã³100ÎŒãå ããå 容ç©ã
ãããŸãåæ··åæ©ã§æ··åãããã€ãã§è©Šéšç®¡ãäž
è¿°ã®æ¹æ³ãšåæ§ã«ããŠCEAã®æè¡æž ã 125Iâ
CEAããã³äžæº¶åäºæ¬¡æäœã§åŠçãããåèªã¿
åãå€ããæšæºæ²ç·ãäœæããæ£è è¡æŒ¿ãµã³ãã«
ã«ã€ããŠåŸãããå€ãšæ¯èŒããã 第ïŒè¡šã¯äŸïŒã®åŸæ¥æ³ã®éææ³ã§åŸããããµã³
ãã«ã«ã€ããŠã®çµæãããã³äŸïŒã®æ¬çºæã®æ¹æ³
ã§åŸããããµã³ãã«ã«ã€ããŠã®çµæã§ããã 第ïŒè¡šã®çµæã¯ãCEAæ¿åºŠ20nïœïŒmlãŸã§ã¯äŸ
ïŒããã³äŸïŒã®æ¹æ³ãããçžé¢ããçžé¢ä¿æ°ã¯
0.963ãåŸé ã¯1.03ã§ããããšã瀺ããŠããã
ãè¡šã
äŸ ïŒ
äŸïŒã®æ¹æ³ã§å®éãããµã³ãã«ã®å Žåããµã³ã
ã«äžã®CEAæ¿åºŠã20nïœïŒmlãè¶ãããšãã«ã¯ã
ã®ãããªæ¿åºŠã®å Žåã®åŸæ¥ã®æž¬å®æ³ã«ãããã€ãŠ
以äžã®ããã«å®éãå®æœããã è¡æŒ¿ãµã³ãã«ïŒ50ÎŒïŒãé ¢é žã¢ã³ã¢ããŠã ç·©
è¡æ¶²ïŒé ¢é žå¡©0.01MãPH6.8ïŒïŒmlãå«ãè©Šéšç®¡
ã«ãšã€ããåè©Šéšç®¡ã«CEAæè¡æž 25ÎŒãå ãã
å 容ç©ããããŸãåæ··åæ©ã§æ··åãããè©Šéšç®¡ã
45âã§30åéã€ã³ããŠããŒããããã€ãã§åè©Šéš
管㫠125IâCEA25ÎŒãå ããã€ãã§è©Šéšç®¡ã45
âã§30åéãåã³ã€ã³ããŠããŒããããåè©Šéšç®¡
ã«èš2.5mlã®ãžã«ã³ãã«ãã¹ããšãŒãã²ã«PH6.25
ãå ããå 容ç©ã1000Ãïœã§ïŒåéé å¿åé¢ã
ããäžæŸæ¶²ãé€å»ããé ¢é žã¢ã³ã¢ããŠã ç·©è¡æ¶²
ïŒPH6.25ïŒïŒmlãæ··åããªããå ãããè©Šéšç®¡ã®
å 容ç©ãååãšåæ§ã«åã³é å¿åé¢ããäžæŸæ¶²ã
é€å»ãããæ®ã€ãã²ã«äžã®çµå 125IâCEAãã¬
ã³ããŒã·ã³ãã¬ãŒã·ãšã³ã«ãŠã³ã¿ãŒã¹ãã¯ããã¡
ãŒã¿ãŒã§ïŒåéã«ãŠã³ãããŠå®éããã æšæºé»æ¢æ²ç·ã¯æ¬¡ã®ããã«ããŠäœæããã è©Šéšç®¡ã察ã«ããåè©Šéšç®¡ã«0.01Mé ¢é žå¡©ç·©è¡
液ïŒPH6.8ïŒ5.0mlãå ãããåè©Šéšç®¡ã«æ£åžžãã
è¡æŒ¿50ÎŒãå ããå 容ç©ãå®å šã«æ··åãããå
察ã®è©Šéšç®¡ã«æšæºéã®CEAããªãã¡ïŒã1.25ã
3.125ã6.25ããã³12.5nïœïŒmlCEA掻æ§ã«çžåœã
ãïŒã10ã25ã50ããã³100ÎŒãå ããå 容ç©
ããããŸãåæ··åæ©ã§æ··åãããã€ãã§è©Šéšç®¡ã
äžè¿°ã®å Žåãšåæ§ã«ããŠCEAã«å¯Ÿããæè¡æž ã
ãã³ 125IâCEAã§åŠçãããåèªã¿åãå€ãã
æšæºæ²ç·ãäœæããæ£è è¡æŒ¿ãµã³ãã«ã«ã€ããŠåŸ
ãããå€ãšæ¯èŒããã æ¬çºæã®äŸïŒã®æ¹æ³ã§åäžã®ãµã³ãã«ã«ã€ããŠ
ãåæãè¡ããçµæã第ïŒè¡šã«æ¯èŒããã 第ïŒè¡šã«ç€ºããçµæã¯ãæ¬çºæã®ååŠçœ®æ³ã
CEAæ¿åºŠ20nïœïŒmlãè¶ããŠãæ£ç¢ºãªå®éå€ãäž
ããããšã瀺ããŠãããæ¬äŸã«ãããŠè©Šéšãµã³ã
ã«ãåžéããŠCEAæ¿åºŠã20nïœïŒml以äžãšããŠã
äŸïŒã®æ¹æ³ã§åžéãµã³ãã«ã«ã€ããŠè¡ã€ãå®éã«
ããã°ãæ¬çºæã®æ¹æ³ãåŸæ¥ã®æ¬äŸã«èšè¿°ããæ¹
æ³ããããé«ãCEAæ¿åºŠã«ã€ããŠã¯ããæ£ç¢ºãª
å€ãäžããããšã瀺ããŠããã
ã«äžã®CEAæ¿åºŠã20nïœïŒmlãè¶ãããšãã«ã¯ã
ã®ãããªæ¿åºŠã®å Žåã®åŸæ¥ã®æž¬å®æ³ã«ãããã€ãŠ
以äžã®ããã«å®éãå®æœããã è¡æŒ¿ãµã³ãã«ïŒ50ÎŒïŒãé ¢é žã¢ã³ã¢ããŠã ç·©
è¡æ¶²ïŒé ¢é žå¡©0.01MãPH6.8ïŒïŒmlãå«ãè©Šéšç®¡
ã«ãšã€ããåè©Šéšç®¡ã«CEAæè¡æž 25ÎŒãå ãã
å 容ç©ããããŸãåæ··åæ©ã§æ··åãããè©Šéšç®¡ã
45âã§30åéã€ã³ããŠããŒããããã€ãã§åè©Šéš
管㫠125IâCEA25ÎŒãå ããã€ãã§è©Šéšç®¡ã45
âã§30åéãåã³ã€ã³ããŠããŒããããåè©Šéšç®¡
ã«èš2.5mlã®ãžã«ã³ãã«ãã¹ããšãŒãã²ã«PH6.25
ãå ããå 容ç©ã1000Ãïœã§ïŒåéé å¿åé¢ã
ããäžæŸæ¶²ãé€å»ããé ¢é žã¢ã³ã¢ããŠã ç·©è¡æ¶²
ïŒPH6.25ïŒïŒmlãæ··åããªããå ãããè©Šéšç®¡ã®
å 容ç©ãååãšåæ§ã«åã³é å¿åé¢ããäžæŸæ¶²ã
é€å»ãããæ®ã€ãã²ã«äžã®çµå 125IâCEAãã¬
ã³ããŒã·ã³ãã¬ãŒã·ãšã³ã«ãŠã³ã¿ãŒã¹ãã¯ããã¡
ãŒã¿ãŒã§ïŒåéã«ãŠã³ãããŠå®éããã æšæºé»æ¢æ²ç·ã¯æ¬¡ã®ããã«ããŠäœæããã è©Šéšç®¡ã察ã«ããåè©Šéšç®¡ã«0.01Mé ¢é žå¡©ç·©è¡
液ïŒPH6.8ïŒ5.0mlãå ãããåè©Šéšç®¡ã«æ£åžžãã
è¡æŒ¿50ÎŒãå ããå 容ç©ãå®å šã«æ··åãããå
察ã®è©Šéšç®¡ã«æšæºéã®CEAããªãã¡ïŒã1.25ã
3.125ã6.25ããã³12.5nïœïŒmlCEA掻æ§ã«çžåœã
ãïŒã10ã25ã50ããã³100ÎŒãå ããå 容ç©
ããããŸãåæ··åæ©ã§æ··åãããã€ãã§è©Šéšç®¡ã
äžè¿°ã®å Žåãšåæ§ã«ããŠCEAã«å¯Ÿããæè¡æž ã
ãã³ 125IâCEAã§åŠçãããåèªã¿åãå€ãã
æšæºæ²ç·ãäœæããæ£è è¡æŒ¿ãµã³ãã«ã«ã€ããŠåŸ
ãããå€ãšæ¯èŒããã æ¬çºæã®äŸïŒã®æ¹æ³ã§åäžã®ãµã³ãã«ã«ã€ããŠ
ãåæãè¡ããçµæã第ïŒè¡šã«æ¯èŒããã 第ïŒè¡šã«ç€ºããçµæã¯ãæ¬çºæã®ååŠçœ®æ³ã
CEAæ¿åºŠ20nïœïŒmlãè¶ããŠãæ£ç¢ºãªå®éå€ãäž
ããããšã瀺ããŠãããæ¬äŸã«ãããŠè©Šéšãµã³ã
ã«ãåžéããŠCEAæ¿åºŠã20nïœïŒml以äžãšããŠã
äŸïŒã®æ¹æ³ã§åžéãµã³ãã«ã«ã€ããŠè¡ã€ãå®éã«
ããã°ãæ¬çºæã®æ¹æ³ãåŸæ¥ã®æ¬äŸã«èšè¿°ããæ¹
æ³ããããé«ãCEAæ¿åºŠã«ã€ããŠã¯ããæ£ç¢ºãª
å€ãäžããããšã瀺ããŠããã
ãè¡šã
ãè¡šã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ïŒïŒïŒããïŒïŒ50ã«åžéããã®ã«ååãªéã®
æ°Žãããè¡æž ãŸãã¯è¡æŒ¿ãµã³ãã«ã«å ããåžéãµ
ã³ãã«ã85âã105âã®æž©åºŠã«ïŒåãã30åå ç±
ããã€ãã§ãµã³ãã«äžã®å®é劚害ç©è³ªãäžåãã
ããšãç¹åŸŽãšããçèæåæ¿åºŠæž¬å®çšããè¡æž ãŸ
ãã¯è¡æŒ¿ãµã³ãã«ã®ååŠçœ®æ¹æ³ã ïŒ ãµã³ãã«ãïŒïŒ16ã«åžéããç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®æ¹æ³ã ïŒ åžéãµã³ãã«ãïŒåãã10åå ç±ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé ãŸãã¯ç¬¬ïŒé ã®ããããäžã€ã«èš
èŒã®æ¹æ³ã ïŒ ãµã³ãã«ã95âã«å ç±ããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé ã第ïŒé ã®ããããäžã€ã«èšèŒã®æ¹æ³ã ïŒ ãµã³ãã«ã®åžéã«äœ¿çšããæ°Žã¯ãµã³ãã«ã®PH
ã7.5ããïŒã«ç·©è¡åããã®ã«é©åœãªç·©è¡æ¶²ã®å
åéãå«æããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®
ããããäžã€ã«èšèŒã®æ¹æ³ã
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/120,017 US4299815A (en) | 1980-02-08 | 1980-02-08 | Carcinoembryonic antigen determination |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS56126763A JPS56126763A (en) | 1981-10-05 |
JPS6353510B2 true JPS6353510B2 (ja) | 1988-10-24 |
Family
ID=22387781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1677081A Granted JPS56126763A (en) | 1980-02-08 | 1981-02-06 | Pretreatment of human ceram and plasma sample |
Country Status (8)
Country | Link |
---|---|
US (1) | US4299815A (ja) |
EP (1) | EP0033960A3 (ja) |
JP (1) | JPS56126763A (ja) |
AU (1) | AU6696781A (ja) |
CA (1) | CA1140045A (ja) |
DK (1) | DK51481A (ja) |
ES (1) | ES499227A0 (ja) |
NO (1) | NO810423L (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU543007B2 (en) * | 1980-04-15 | 1985-03-28 | Technicon Instruments Corportion | Agglutination immunoassay |
US6713619B1 (en) | 1980-08-29 | 2004-03-30 | Massachusetts Institute Of Technology | Oncogenes and methods for their detection |
US4535058A (en) * | 1982-10-01 | 1985-08-13 | Massachusetts Institute Of Technology | Characterization of oncogenes and assays based thereon |
EP0072902B1 (de) * | 1981-08-21 | 1985-04-24 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Bestimmung von carcinoembryonalem Antigen (CEA) und zur Bestimmung geeignete Antikörperlösung |
US4578349A (en) * | 1982-04-08 | 1986-03-25 | Abbott Laboratories | Immunoassay for carcinoembryonic antigen (CEA) |
JPH0811075B2 (ja) * | 1982-06-30 | 1996-02-07 | éæ²» æŸå²¡ | åã¯ããŒã³æ§æïœïœ ïœæäœ |
US4631254A (en) * | 1982-12-06 | 1986-12-23 | Hoffmann-La Roche Inc. | Carcinoembryonic antigen determination |
IT1174800B (it) * | 1983-11-21 | 1987-07-01 | Alberto Bartorelli | Metodo per la determinazione di immunoglobuline umane specifiche per gli antigeni dei carcinomi umani e sua utilizzazione nella sierodiognosi di forme primitive tumorali |
GB8427006D0 (en) * | 1984-10-25 | 1984-11-28 | Iq Bio Ltd | Determination of chlamydia trachomatis |
US5026653A (en) * | 1985-04-02 | 1991-06-25 | Leeco Diagnostic, Inc. | Scavenger antibody mixture and its use for immunometric assay |
JPH0792454B2 (ja) * | 1986-08-04 | 1995-10-09 | æ æ²» ç³å· | æåã®æž¬å®æ¹æ³ |
US6013772A (en) * | 1986-08-13 | 2000-01-11 | Bayer Corporation | Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays |
US4900684A (en) * | 1987-06-01 | 1990-02-13 | Immunomedics, Inc. | CEA immunoassay free of human anti-mouse antibody false positives |
US4978632A (en) * | 1988-12-15 | 1990-12-18 | Kallestad Diagnostics, Inc. | Method of pre-treating samples in peroxidase-catalyzed enzyme assays |
DE3939052C2 (de) * | 1989-11-25 | 2003-11-06 | Pipelife Rohrsysteme Gmbh | Verfahren zur Herstellung eines ÃŒber Muffenverbindungen mit einem gleichen oder einem anderen Rohr verbindbaren Leitungsrohres aus Kunststoff |
US5532135A (en) * | 1990-02-02 | 1996-07-02 | Cancer Research Fund Of Contra Costa | Solid-phase competitive assay utilizing a fusion protein |
JPH07500411A (ja) * | 1991-02-05 | 1995-01-12 | ãã¡ãã¯ãã»ã£ã㣠| çèå æ§æåãæ€åºããããã®ç°¡ææ€æ»æ³ |
US6949629B2 (en) * | 2002-03-13 | 2005-09-27 | Aspenbio, Inc. | Methods for purifying selected CEA family member proteins |
CA2763727A1 (en) * | 2009-06-26 | 2010-12-29 | Atlas Antibodies Ab | Improvement of immunodetectability |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3867363A (en) * | 1970-06-01 | 1975-02-18 | Hans John Hansen | Carcinoembryonic antigens |
US3697638A (en) * | 1970-06-01 | 1972-10-10 | Hoffmann La Roche | Antigens |
US3663684A (en) * | 1970-06-01 | 1972-05-16 | Hoffmann La Roche | Carcinoembryonic antigen and diagnostic method using radioactive iodine |
US4180499A (en) * | 1971-01-27 | 1979-12-25 | Hoffmann-La Roche Inc. | Carcinoembryonic antigens |
US4140753A (en) * | 1976-04-30 | 1979-02-20 | Scripps Clinic & Research Foundation | Diagnostic method and reagent |
US4098876A (en) * | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4180556A (en) * | 1977-03-09 | 1979-12-25 | Abbott Laboratories | Pretreatment method for carcinoembryonic antigen assay |
-
1980
- 1980-02-08 US US06/120,017 patent/US4299815A/en not_active Expired - Lifetime
-
1981
- 1981-02-05 DK DK51481A patent/DK51481A/da not_active Application Discontinuation
- 1981-02-06 CA CA000370264A patent/CA1140045A/en not_active Expired
- 1981-02-06 AU AU66967/81A patent/AU6696781A/en not_active Abandoned
- 1981-02-06 NO NO810423A patent/NO810423L/no unknown
- 1981-02-06 JP JP1677081A patent/JPS56126763A/ja active Granted
- 1981-02-06 EP EP81100863A patent/EP0033960A3/de not_active Ceased
- 1981-02-07 ES ES499227A patent/ES499227A0/es active Granted
Also Published As
Publication number | Publication date |
---|---|
AU6696781A (en) | 1981-08-13 |
US4299815A (en) | 1981-11-10 |
NO810423L (no) | 1981-08-10 |
EP0033960A2 (de) | 1981-08-19 |
DK51481A (da) | 1981-08-09 |
ES8205062A1 (es) | 1982-06-01 |
EP0033960A3 (de) | 1982-04-14 |
JPS56126763A (en) | 1981-10-05 |
CA1140045A (en) | 1983-01-25 |
ES499227A0 (es) | 1982-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6353510B2 (ja) | ||
US4062935A (en) | Immunoassay involving the binding of RF to the antigen-antibody complex | |
US4434236A (en) | Immunoassay wherein labeled antibody is displaced from immobilized analyte-analogue | |
US4241176A (en) | Magnetic gel suitable to immunoenzymatic determinations | |
Brock et al. | Direct solid-phase 125I radioimmunoassay of serum cortisol. | |
JPS58117455A (ja) | æäœãæ€åºåã³å®éããæ¹æ³ | |
EP0061857B1 (en) | Particle agglutination assay | |
US4804625A (en) | Assay procedures | |
JPS60259964A (ja) | åæè©Šæäžã®å ç«åŠçã«æŽ»æ§ãªç©è³ªã®å®éæ³ | |
US4283383A (en) | Analysis of biological fluids | |
US4138213A (en) | Agglutination immunoassay of immune complex with RF or Clq | |
US3658982A (en) | Stable latex reagent for the detection of rheumatoid arthritis | |
JPH01248061A (ja) | è©Šéšãããããã³å ç«ãªã¬ã³ãã®æž¬å®æ¹æ³ | |
JPH0616044B2 (ja) | å ç«åŠçã©ããã¯ã¹åéæ³ | |
US4272504A (en) | Antibody adsorbed support method for carcinoembryonic antigen assay | |
US3872225A (en) | Process of viral diagnosis and reagent | |
JPS6327658B2 (ja) | ||
JPS6243501B2 (ja) | ||
US4631254A (en) | Carcinoembryonic antigen determination | |
JPS6224745B2 (ja) | ||
JP3618797B2 (ja) | å ç«æž¬å®æ³ | |
US4403040A (en) | Diagnostic test for the detection of a specific tumor antigen with CoA-SPC | |
CA1059901A (en) | Direct radioimmunoassay for antigens and their antibodies | |
JPH04203967A (ja) | 埮éæåã®è¿ é枬å®æ¹æ³ | |
JPH08193999A (ja) | å ç«æž¬å®æ³ |